Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Downgrades BioCryst Pharmaceuticals to Perform

Oppenheimer analyst Justin Kim downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Outperform to Perform.
byBenzinga Newsdesk
August 5, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Justin Kim downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Outperform to Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts